ArticleEBioMedicine2020
Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis.
Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora.Orphanet journal of rare diseases · 2024Trial
- Article
- Potential Benefits of Metformin Via Roseburia Intestinalis in High-fat Diet-fed Mice With Colorectal Adenomas.Probiotics and antimicrobial proteins · 2026Article
- Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.Frontiers in pharmacology · 2026Review
- A critical role forActa pharmaceutica Sinica. B · 2025Article
- From gut to proteomics: the impact ofFrontiers in oncology · 2025Article
- Exploring the role of Fusobacterium nucleatum in colorectal cancer: implications for tumor proliferation and chemoresistance.Cell communication and signaling : CCS · 2024Review
- Targeting the gut microbiota: a new strategy for colorectal cancer treatment.Journal of translational medicine · 2024Review
- Integrated Analysis of Gut Microbiome and Adipose Transcriptome Reveals Beneficial Effects of Resistant Dextrin from Wheat Starch on Insulin Resistance in Kunming Mice.Biomolecules · 2024Article
- Metformin and its potential influence on cell fate decision between apoptosis and senescence in cancer, with a special emphasis on glioblastoma.Frontiers in oncology · 2024Review
- Current status and frontier tracking of clinical trials on Metformin for cancer treatment.Journal of cancer research and clinical oncology · 2023Review
- Identification of Gut Microbiota Profile Associated with Colorectal Cancer in Saudi Population.Cancers · 2023Article
- Male-Biased Gut Microbiome and Metabolites Aggravate Colorectal Cancer Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Metformin: update on mechanisms of action and repurposing potential.Nature reviews. Endocrinology · 2023Review
- Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing.Journal of translational medicine · 2023Review
- Why Does Obesity as an Inflammatory Condition Predispose to Colorectal Cancer?Journal of clinical medicine · 2023Review
- The role of gut microbiota and drug interactions in the development of colorectal cancer.Frontiers in pharmacology · 2023Review
- Effect of gut microbiota on colorectal cancer progression and treatment.Saudi medical journal · 2022Article
- Mechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effect of metformin on gut microbiota has been reported, but whether metformin can suppress colorectal cancer (CRC) by affecting gut microbiota composition and rescue F. nucleatum-induced tumourigenicity remains unclear.
methodsTo identify microbiota associated with both CRC occurrence and metformin treatment, first, we reanalyzed the gut microbiome of our previous data on two human cohorts of normal and CRC individuals. Subsequently, we summarized microbiota altered by metformin from published literatures. Several taxa, including Fusobacterium, were associated with both CRC occurrence and metformin treatment. We investigated the effect of metformin on APC
findingsWe summarized 131 genera altered by metformin from 18 published literatures. Five genera reported to be changed by metformin, including Bacteroides, Streptococcus, Achromobacter, Alistipes and Fusobacterium, were associated with CRC in both of our human cohorts. Metformin relieved the symptoms caused by F. nucleatum administration in APC
interpretationThis study pioneers in predicting critical CRC-associated taxa contributing to the antitumour effect of metformin, and correlating gut microbiome with the antitumour effect of metformin in experimental animals. We presented a basis for future investigations into metformin's potential effect on suppressing F. nucleatum-induced tumor formation in vivo.
fundingThis work was supported by grants from the National Natural Science Foundation of China (31701250).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.